Cefazolin sodium salt Property

Melting point:

190 °C

refractive index 

20 ° (C=10, H2O)

storage temp. 

Keep in dark place,Inert atmosphere,2-8°C

solubility 

H₂O: 50 mg/mL, clear, colorless

form 

crystalline powder

color 

White to Off-White

Sensitive 

Light Sensitive

Merck 

14,1917

BRN 

3585038

Stability:

Stable, but may be heat sensitive - store in cool conditions. May discolour upon exposure to light - store in the dark. Incompatible with strong oxidizing agents.

InChI

InChI=1/C14H14N8O4S3.Na.H/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21;;/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26);;/t9-,12-;;/s3

InChIKey

LJIOGPYKTPCRAP-MVOALHSDNA-N

SMILES

C(C1=C(CS[C@]2([H])[C@H](NC(=O)CN3N=NN=C3)C(=O)N12)CSC1=NN=C(C)S1)(=O)O.[NaH] |&1:5,7,r|

LogP

1.133 (est)

CAS DataBase Reference

27164-46-1(CAS DataBase Reference)

Safety

Hazard Codes 

Xn,Xi

Risk Statements 

42/43-36/37/38-20/21/22

Safety Statements 

22-36/37-36-26

WGK Germany 

2

RTECS 

XI0390000

HS Code 

29349990

Toxicity

LD50 in mice, rats (mg/kg): 3.9, 3.18 i.v.; 6.2, 7.4 i.p. (Birkhead)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H317May cause an allergic skin reaction

H334May cause allergy or asthma symptoms or breathing difficulties if inhaled

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P342+P311IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.

Cefazolin sodium salt Chemical Properties,Usage,Production

Brand Name(s) in US

Ancef, Kefzol, and generic

Description

Cefazolin was synthesized by Fujisawa Pharmaceutical Co. in 1969. It was the first of the cephem antibiotics to introduce a thiadiazolylthiomethyl group at the 3 position and a tetrazole group at the 7 position in the side chain. Cefazolin is a parenteral cephem antibiotic showing better activity against gramnegative bacteria than cephalothin or cephaloridine. Its bactericidal activity, tissue distribution, and urinary excretion are excellent and it has wide clinical use.

Chemical Properties

White to off-white powder

Originator

Cefamedin,Fujisawa,Japan,1971

Uses

Semi-synthetic antibiotic derived from 7-amino-cepphalosporanic acid. An antibacterial

Uses

enzyme inhibitor, Gaucher's disease therapy

Uses

Semi-synthetic antibiotic derived from 7-amino-cephalosporanic acid. An antibacterial.

Definition

ChEBI: A cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.

Manufacturing Process

7-Aminocephalosporanic acid is converted to its sodium salt and acylated with 1H-tetrazole-1-acetyl chloride. The acetoxy group is then displaced by reaction with 5-methyl-1,3,4-thiadiazole-2-thiol in buffer solution. The product acid is converted to the sodium salt by NaHCO3.

brand name

Ancef (GlaxoSmithKline); Kefzol (Lilly).

Therapeutic Function

Antibacterial

Biological Activity

cefazolin is a semisynthetic antibiotic with a broad spectrum of antibacterial activity. cefazolin has exhibited high activity against gram-positive bacteria and gram-negative bacteria [1].

Clinical Use

Cefazolin (Ancef, Kefzol) is one of a series of semisyntheticcephalosporins in which the C-3 acetoxy function has beenreplaced by a thiol-containing heterocycle—here, 5-methyl-2-thio-1,3,4-thiadiazole. It also contains the somewhatunusual tetrazolylacetyl acylating group. Cefazolin wasreleased in 1973 as a water-soluble sodium salt. It is activeonly by parenteral administration.
Cefazolin provides higher serum levels, slower renalclearance, and a longer half-life than other first-generationcephalosporins. It is approximately 75% protein bound inplasma, a higher value than for most other cephalosporins.Early in vitro and clinical studies suggest that cefazolin ismore active against Gram-negative bacilli but less activeagainst Gram-positive cocci than either cephalothin orcephaloridine. Occurrence rates of thrombophlebitis followingintravenous injection and pain at the site of intramuscularinjection appear to be the lowest of the parenteralcephalosporins.

Veterinary Drugs and Treatments

In the United States, there are no cefazolin products approved for veterinary species but it has been used clinically in several species when an injectable, first generation cephalosporin is indicated. It is used for surgical prophylaxis, and for variety of systemic infections (including orthopedic, soft tissue, sepsis) caused by susceptible bacteria. Most commonly given every 6 – 8 hours via parenteral routes, cefazolin constant rate intravenous infusion protocols are being developed as cefazolin is a time (above MIC)-dependent antibiotic, and serum/tissue concentrations can remain above MIC.

in vitro

in cultured mg-63 human osteosarcoma cell line, cefazolin (100 μg/ml) showed little or no effect on osteoblast replication. cefazolin (200μg/ml) significantly decreased cell replication, and 10,000 μg/ml caused cell death [2].

in vivo

in patients with normal and various degrees of compromised renal function, administration of cefazolin significantly decreased the urinary concentration and percentage of the dose excreted in the urine [3]. the half-life of cefazolin in serum of normal persons was 1.9 hr and as long as 35 hr in severely uremic patients. in uremic patients, cefazolin was well tolerated [4].

References

[1] kariyone k, harada h, kurita m, et al. cefazolin, a new semisynthetic cephalosporin antibiotic. i[j]. the journal of antibiotics, 1970, 23(3): 131-136.
[2] edin m l, miclau t, lester g e, et al. effect of cefazolin and vancomycin on osteoblasts in vitro[j]. clinical orthopaedics and related research, 1996, 333: 245-251.
[3] levison m e, levison s p, ries k, et al. pharmacology of cefazolin in patients with normal and abnormal renal function[j]. journal of infectious diseases, 1973, 128(supplement 2): s354-s357.
[4] craig w a, welling p g, jackson t c, et al. pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency[j]. journal of infectious diseases, 1973, 128(supplement 2): s347-s353.